The Challenge of Rising PSA. Can We Delay Prostate Cancer Progression?
|
AstraZeneca-Sponsored Satellite Symposium, EAU, Geneva, April 2001
|
Supplement Issue: European Urology 2001, Vol. 40, Suppl. 2
In recent years the incidence of patients presenting with early prostate cancer has increased. Treatment options include localized therapies of primary curative intent (radical prostatectomy or radiotherapy), hormonal therapy or “watchful waiting”. Despite potentially curative treatment, many patients with early prostate cancer experience prostate-specific antigen (PSA) progression. PSA is typically elevated in prostate cancer, but diagnosis by biopsy is critical. A common problem facing clinicians is how to manage patients with elevated PSA levels but negative biopsies.
In this special issue Laurent Boccon-Gibod describes studies investigating the efficiency of a range of biopsy protocols and concludes that extended biopsy procedures that sample the periphery of tshe gland should be used as a means of improving tumor detection. Peter Carroll describes potential reasons for PSA progression, how prognosis can be predicted from the rate and timing of rising PSA level and treatment options available. Manfred Wirth considers whether adjuvant treatments are able to delay the progression of patients with early prostate cancer. John Anderson covers the influence that treatment options have on patient quality of life.
The Challenge of Rising PSA. Can We Delay Prostate Cancer Progression?
AstraZeneca-Sponsored Satellite Symposium, EAU, Geneva, April 2001
Editor(s):
Kirby, R. (London)
IV + 30 p.,
11 fig.,
7 tab.,
soft cover,
2001
Status: available
 |
|
|
|
|
| |
CHF |
EUR |
USD |
|
| |
|
(Germany only) |
(USA only) |
|
| List price |
29.- |
20.50 |
25.25 |
|
|
| Prices subject to change |
Order this title
 Print Edition
Online Edition
Order Information
ISBN: 978-3-8055-7324-5
e-ISBN: 978-3-318-00788-6
|
|
|
| Search in this book
|
|
|
|
Title Index
Book Series
Urology